(FLXN) – Flexion Therapeutics: Fourth Quarter Revenue Statistics
Actions of Flexion remedy (NASDAQ: FLXN) rose in aftermarket buying and selling after the corporate launched its fourth quarter outcomes.
Earnings per share rose 57.47% over the previous yr to ($ 0.37), which beat the estimate of ($ 0.46).
Income of $ 26,310,000 elevated 11.23% yr over yr, lacking the estimate of $ 27,340,000.
The corporate has not launched a income forecast presently.
Flexion Therapeutics has not launched a income forecast presently.
Convention name particulars
Date: March 10, 2021
Time: 4:30 p.m.
Webcast URL AND: https://edge.media-server.com/mmc/p/nrb494gb
Latest fairness efficiency
Firm excessive in 52 weeks was at $ 14.39
52 week low: $ 5.01
Value motion within the final quarter: Down 3.58%
Flexion Therapeutics Inc is a United States-based specialty pharmaceutical firm. The corporate is targeted on the event and commercialization of recent native therapies. The corporate specializes within the remedy of sufferers with musculoskeletal issues starting with osteoarthritis. The merchandise supplied by the corporate are zilretta which is used to boost the scientific impact of intra-articular corticosteroid remedy.